Cogent says PEAK Phase 3 trial shows bezuclastinib-sunitinib combo extends PFS in second-line GIST

Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGT

0.00
  • Cogent Biosciences detailed Phase 3 PEAK results at the 2026 ASCO annual meeting for bezuclastinib with sunitinib in second-line GIST.
  • The combination extended the time patients lived without disease worsening versus sunitinib alone, supporting a potential new standard of care.
  • Benefit held across genetic subgroups, strengthening the commercial case across a broad second-line GIST population.
  • FDA granted Priority Review for the combination in GIST previously treated with imatinib, with a PDUFA date set for Nov. 30, 2026.
  • A new first-line study started in KIT exon 9 GIST, expanding the program into earlier treatment and a defined genetic segment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605300800PRIMZONEFULLFEED9729094) on May 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.